Remove Drug Development Remove Magazine Remove Vaccines
article thumbnail

DoH – Abu Dhabi and Sanofi link for vaccine development

Pharmaceutical Technology

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Can pharma tariffs “Make America Manufacture Again”? Credit: Department of Health Abu Dhabi.

article thumbnail

Navigating uncertainty: the future of vaccine oversight amid CDC firings

Pharmaceutical Technology

GlobalData Healthcare June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Changes to ACIP could result in regulatory uncertainty for vaccine developers and manufacturers. Can pharma tariffs “Make America Manufacture Again”?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape

Pharmaceutical Technology

In recent years, the pharmaceutical industry has exhibited a significant shift into digitalisation, with AI pushing for innovation across the entire drug development value chain, from accelerating drug discovery to optimising clinical trial design to ultimately improve patient outcomes.

article thumbnail

UK steps up with £1.25bn Gavi vaccine pledge as US funding disappears

Pharmaceutical Technology

The UK has confirmed its support for global vaccination by pledging £1.25bn to global vaccine group Gavi while the US will halt funding to the international organisation. The Gates Foundation committed $1.6bn for the vaccine alliance, making it the second largest donor. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Further, they say the balance attempted between encouraging innovation and improving access instead could be contradictory for drug developers and investors, in a way that is emblematic of a fragmented EU. Industry reactions have been mixed.

article thumbnail

Madrigal poised to enter European MASH market after CHMP endorsement

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

GRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disorders

pharmaphorum

Can you give a brief overview of why the historical development of new treatments for neurodevelopmental disorders has faced significant challenges? With the right teams and experience in place, drug developers can unlock their full potential, streamline efforts to advance them quickly, and bring more, new options to patients.